Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lies, Damn Lies, And DTC Ads?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Risk Communications Advisory Committee is set to discuss how quantitative risk information can be presented in such a way as to inform rather than mislead consumers.

You may also be interested in...

Risk Communications Panel To Discuss Public Confusion, “Message Fatigue”

FDA advisory committee will again consider whether consumers have an inaccurate understanding of drug risks or are so overwhelmed by messages about them that they discount the warnings.

FDA To Study Impact Of Rx Drug Ads That Provide Disease Information

The agency plans to assess whether the inclusion of disease information in an Rx drug print ad affects consumer perception about the product.

Adverse Events, Direct From The Consumer

FDA's proposed consumer version of the MedWatch form for reporting drug-related adverse events goes before an advisory panel.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts